Drug Trial Radar · NCT03833206
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients
Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jan 15, 2027
Primary completion
Feb 28, 2028
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- BioLite, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- American BriVision Corporation
- First posted
- Feb 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.
Conditions
- Major Depressive Disorder
Interventions
PDC-1421 CapsuleDrug
PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Montgomery-Åsberg Depression Rating Scale (MADRS)Time frame: 5 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Health System
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.